Skip to main content
    I

    Immatics NV (IMTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.17
    -0.22 (-3.44%)

    Market Cap: $972.99M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Immatics NV (IMTX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Immatics NV are Immix Biopharma (IMMX), CureVac NV (CVAC) and Nektar Therapeutics (NKTR). By market cap, Immatics NV ranks 9th of the 13 companies on this page; Immunocore Holdings (IMCR) is the largest at $1.55B.

    Peer Comparison

    IMTX's revenue growth of 33.5% is above the peer median of -2.2%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Immatics NV (IMTX)$972.99MN/A17.7x0.0%N/A33.5%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    CureVac NV (CVAC)$1.05BN/A1.8x182.1%N/A-89.0%0.00%
    Nektar Therapeutics (NKTR)$1.27BN/A23.9x0.0%N/A-20.4%0.00%
    DBV Technologies (DBVT)$692.19MN/AN/A0.0%-130.3%-42.9%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Intellia Therapeutics Inc (NTLA)$1.36BN/A26.1x0.0%-50.0%-48.0%0.00%
    Nuvectis Pharma Inc (NVCT)$696.03MN/AN/A0.0%N/A0.0%0.00%
    Immunocore Holdings Ltd (IMCR)$1.55BN/A2.8x-7.5%-0.5%-1.4%0.00%
    MoonLake Immunotherapeutics (MLTX)$1.06BN/AN/A0.0%-54.6%0.0%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Jade Biosciences, Inc. (JBIO)$1.03BN/AN/A0.0%N/A0.0%0.00%
    Novavax Inc (NVAX)$1.41BN/A3.2x-18.6%-66.6%-3.0%0.00%
    Peer median$1.06B95.1x5.8x0.0%-52.3%-2.2%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Immatics NV, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    CureVac NV (CVAC)
    CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA).
    Nektar Therapeutics (NKTR)
    Nektar Therapeutics is a biopharmaceutical company.
    NKTR competitors
    DBV Technologies (DBVT)
    DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products.
    DBVT competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    Intellia Therapeutics Inc (NTLA)
    Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
    NTLA competitors
    Nuvectis Pharma Inc (NVCT)
    Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer.
    NVCT competitors
    Immunocore Holdings Ltd (IMCR)
    Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases.
    IMCR competitors
    MoonLake Immunotherapeutics (MLTX)
    MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug...
    MLTX competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Jade Biosciences, Inc. (JBIO)
    Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune...
    JBIO competitors
    Novavax Inc (NVAX)
    Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases...
    NVAX competitors

    Frequently Asked Questions About IMTX

    Who are Immatics NV's main competitors?

    The companies most similar to Immatics NV include Immix Biopharma (IMMX), CureVac NV (CVAC), Nektar Therapeutics (NKTR), DBV Technologies (DBVT) and Theravance Biopharma (TBPH), listed from the closest match.

    Who is Immatics NV's biggest competitor?

    Immunocore Holdings (IMCR) is the largest of the similar companies at $1.55B; Immix Biopharma (IMMX) is the closest match by business profile, size, sector and industry.

    How does IMTX stock compare with its competitors?

    IMTX's P/S is 17.7x against a peer median of 5.8x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Immatics NV's competitors pays a higher dividend?

    Immatics NV pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Immatics NV bigger than its competitors?

    No. Immatics NV is 9th by market cap among the 13 companies on this page; the largest is Immunocore Holdings (IMCR) at $1.55B.